Next-gen Covid-19 vaccines: Elicio and its lymph node targeting approach

PHARMACEUTICAL TECHNOLOGY One next-generation Covid-19 vaccine that is about to enter clinical studies is Elicio’s ELI-005. This lymph node-targeting vaccine is composed of an adjuvant developed using the company’s Amphiphile technology and the SARS-CoV-2 virus’s spike protein RBD. Elicio head of research and development Christopher Haqq explains the differentiated mechanism of the action of this vaccine and its promise in conferring enduring T cell immunity to Covid-19. FULL STORY